Your browser doesn't support javascript.
loading
Fibrinogen-to-lymphocyte Ratio Predicts the Outcomes of Hypopharyngeal Squamous Cell Carcinoma Treated With Definitive Radiotherapy.
Sato, Kaname; Hatakeyama, Hiromitsu; Okada, Hanako; Kawano, Masako; Yoshida, Kohei; Oki, Yamato; Kuwahara, Tatsu; Niwa, Kazutomo; Isono, Yasuhiro; Oridate, Nobuhiko.
Afiliação
  • Sato K; Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan.
  • Hatakeyama H; Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan; htkym@yokohama-cu.ac.jp.
  • Okada H; Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan.
  • Kawano M; Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan.
  • Yoshida K; Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan.
  • Oki Y; Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan.
  • Kuwahara T; Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan.
  • Niwa K; Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan.
  • Isono Y; Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan.
  • Oridate N; Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
In Vivo ; 37(3): 1281-1289, 2023.
Article em En | MEDLINE | ID: mdl-37103064
BACKGROUND/AIM: Previous studies have identified several inflammatory biomarkers that are useful as prognostic biomarkers for various cancer types. However, the fibrinogen-to-lymphocyte ratio (FLR) has not been addressed in head and neck squamous cell carcinoma. Here, we aimed to examine the value of pretreatment FLR as a prognostic marker in patients who received definitive radiotherapy for hypopharyngeal squamous cell carcinoma (HpSCC). PATIENTS AND METHODS: This retrospective study included 95 patients treated with definitive radiotherapy for HpSCC between 2013 and 2020. The prognostic factors for progression-free (PFS) and overall (OS) survival were identified. RESULTS: The optimal cut-off value of pretreatment FLR for discriminating PFS was 2.46. Based on this value, 57 and 38 patients were classified into groups with high and low FLR, respectively. A high FLR was significantly associated with advanced local disease and overall stage, and with the development of synchronous second primary cancer compared with a low FLR. The high FLR group had significantly lower PFS and OS rates than the low FLR group. Multivariate analysis showed that having a high pretreatment FLR was an independent prognostic factor for poorer PFS and OS [PFS: hazard ratio (HR)=2.14, 95% confidence interval (CI)=1.09-4.19, p=0.026; OS: HR=2.86, 95% CI=1.14-7.20, p=0.024]. CONCLUSION: The FLR has a clinical effect on PFS and OS in patients with HpSCC, suggesting that it has potential application as a prognostic factor for patients with HpSCC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemostáticos / Carcinoma de Células Escamosas / Neoplasias Hipofaríngeas / Neoplasias de Cabeça e Pescoço Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: In Vivo Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemostáticos / Carcinoma de Células Escamosas / Neoplasias Hipofaríngeas / Neoplasias de Cabeça e Pescoço Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: In Vivo Ano de publicação: 2023 Tipo de documento: Article